SCHEMBL1001208

SCHEMBL1001208

COC(=O)N1CCc2c([nH]c3ncccc23)C1c1ccc(F)cc1F

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.49
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 3/20 0.46
ALDH1A1 P00352 3/20 0.45
GAA P10253 1/20 0.45
TDP1 Q9NUW8 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 2/20 0.43
NPC1 O15118 1/20 0.43
RECQL P46063 1/20 0.43
TP53 P04637 1/20 0.43
ABCB1 P08183 2/20 0.43
ABCG2 Q9UNQ0 2/20 0.43
CHRM3 P20309 1/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KIF11 P52732 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL998810 0.93 ALDH1A1 (0.52) STAT3KDM4ERAB9AMAPTALDH1A1
SCHEMBL997680 0.91 STAT3 (0.47) STAT3KDM4ERAB9AMAPTALDH1A1
SCHEMBL999692 0.90 ABCB1 (0.54) STAT3KDM4ERAB9AMAPTALDH1A1
SCHEMBL999124 0.88 KIF11 (0.50) MAPTTDP1MEN1KMT2ATP53
SCHEMBL997683 0.88 MAPT (0.46) STAT3KDM4ERAB9AMAPTALDH1A1
SCHEMBL998547 0.87 MAPT (0.46) STAT3KDM4ERAB9AMAPTALDH1A1
SCHEMBL998834 0.87 MAPT (0.53) RAB9AMAPTTDP1MEN1KMT2A
SCHEMBL997949 0.86 LMNA (0.45) RAB9AMAPTALDH1A1TDP1MEN1
SCHEMBL999130 0.84 TP53 (0.51) STAT3KDM4ERAB9AMAPTALDH1A1
SCHEMBL999981 0.84 ABCB1 (0.56) RAB9AMAPTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS STAT3 616/4885KDM4E 3424/4885RAB9A 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.